Distributed Registry

Sponsor
Stanford University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03898570
Collaborator
AstraZeneca (Industry)
100
2
9
50
5.6

Study Details

Study Description

Brief Summary

The purpose of this study is to test if a patient can be directly connected to a quality assurance (QA) database, traditionally known as a registry. Patient-reported outcomes (PRO) data will be entered into the database directly from a patient's mobile phone from their index procedure for 12 months. The investigators hope this study to be a "proof of concept" for such a distributed registry and evaluate 1) consistency of data acquisition, 2) engagement of patients, 3) overall value of patient-reported outcomes to enhance long term follow up.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Distributed Registry Study
Actual Study Start Date :
Apr 1, 2019
Anticipated Primary Completion Date :
Sep 30, 2019
Anticipated Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Patients undergoing vascular surgery procedures

Patients will report outcomes via their smartphone.

Behavioral: Patient reported outcomes
Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone. Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys

Outcome Measures

Primary Outcome Measures

  1. Patient Reported Outcomes (PROs) using mobile app [1 Year]

    PROs are any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients with cardiovascular disease who are scheduled or have undergone either a) open or endovascular vascular procedure, or b) open or percutaneous cardiac procedure.

  2. Patients with smartphones (iOS or Android) with unlimited data plans.

  3. Patients who agree to remote surveillance

Exclusion Criteria:
  1. Patients unwilling to download a research study app.

  2. Data plans which are not unlimited.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Palo Alto Veterans Hospital Palo Alto California United States 94305
2 Stanford Palo Alto California United States 94588

Sponsors and Collaborators

  • Stanford University
  • AstraZeneca

Investigators

  • Principal Investigator: Oliver O Aalami, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Oliver O. Aalami, CLINICAL ASSOCIATE PROFESSOR, SURGERY - VASCULAR SURGERY, Stanford University
ClinicalTrials.gov Identifier:
NCT03898570
Other Study ID Numbers:
  • IRB-47517
First Posted:
Apr 2, 2019
Last Update Posted:
May 6, 2019
Last Verified:
May 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2019